Interstitial lung diseases - Where we started from and are now going

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue 1, 2005, Pages 5-12

  Reynolds, Herbert Y ^a,b   Gail, Dorothy B ^a   Kiley, James P ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Hypersensitivity pneumonitis; Idiopathic pulmonary fibrosis; Pulmonary fibrosis; Sarcoidosis

Indexed keywords

ANTIFIBROTIC AGENT; GAMMA INTERFERON;

ALLERGIC PNEUMONITIS; CELLULAR IMMUNITY; DISEASE CLASSIFICATION; FIBROGENESIS; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC DISEASE; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG INJURY; MYOFIBROBLAST; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RESEARCH; REVIEW; SARCOIDOSIS;

ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INTERFERON TYPE II; LUNG DISEASES, INTERSTITIAL; NATIONAL INSTITUTES OF HEALTH (U.S.); PULMONARY ALVEOLI; UNITED STATES;

EID: 15944362522     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Osler W: The principles and practice of medicine - designed for the use of practitioners and students of medicine. New York: D. Appleton and Company 1892: 1-1079. (Section IV: Diseases of Respiratory systems; Chapter IV: Diseases of the Lungs: 3 Chronic Interstitial Pneumonia, pp. 532-6).
2. Hamman L, Rich AR: Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51: 154-63.
3. Amberson JB, Kinghorn HM, Miller JA. et al: Recorded discussion. Trans Am Clin Climatol 1935; 51: 171-7.
4. Hamman L, Rich AR: Acute diffuse interstitial fibrosis of the lungs. Johns Hopkins Med J 1944; 74: 177-212.
5. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY: Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769-78.
6. Liebow AA, Steer A, Billingsley JG: Desquamative interstitial pneumonia. Am J Med 1965; 38: 369-404.
7. Scadding JG, Hinson KFW: Diffuse fibrosising alveolitis (diffuse interstitial fibrosis of the lung) - correlation of histology at biopsy with prognosis. Thorax 1967; 22: 291-304.
8. Turner-Warwick M, Doniach D: Auto-antibody studies in interstitial pulmonary fibrosis. Br Med J 1965; 1: 866.
9. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG: Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-9.
10. Fishman AP: UIP, DIP and all that (editorial). N Engl Med 1978; 298: 843-5.
11. Respiratory Diseases Task Force Report on Problems, Research Approaches. Needs (Chair: Claude Lenfant, M.D.) The Lung Program, National Heart and Lung Institute. DHEW publication # (NIH) 73-432. October 1972. U.S. Government Printing Office, Washington, DC 20402.
12. Ikeda S, Yanai N, Ishikawa S: Flexible bronchofiberscopc. Keio J Med 1968; 17: 1-16.
13. Smiddy JF, Ruth WE, Kerby GR, Renz LE, Raucher C: Flexible fiberoptic bronchoscope (letter). Ann Intern Med 1971; 75: 971.
14. Reynolds HY, Atkinson JP, Newball HH, Frank MM: Receptors for immunoglobulin and complement of human alveolar macrophages. J Immunol 1975; 114: 1813-19.
15. Reynolds HY, Kazmierowski JA, Newball HH: Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest 1975; 56: 376-85.
16. Reynolds HY, Newball HH: Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974; 84: 559-73.
17. Daniele RP, Altose MD, Rowland DR Jr: Immunocompetent cells from the lower respiratory tract of normal human lungs. J Clin Invest 1975; 56: 986-95.
18. Reynolds HY: Use of bronchoalveolar lavage in humans - past necessity and future imperative. Lung 2000; 178: 271-93.
19. McNees P: 50 years of clinical research at the NIH Clinical Center. Pioneering in immunology, pp. 69-71. Warren Grant Magnuson Clinical Center. National Institutes of Health, U.S. Department of Health and Human Services 2003: 1-139.
20. Green GM, The J. Burns Amberson Lecture. In defense of the lung. Am Rev Resp Dis 1970; 102: 691-703.
21. Green GM, Kass EH: The role of the alveolar macrophage in clearance of bacteria from the lung. J Exp Med 1964; 119: 167-75.
22. Pratt SA, Finley TN, Smith MH, Ladman AJ: A comparison of alveolar macrophages and pulmonary surfactant (?) obtained from the lungs of human smokers and nonsmokers by endobronchial lavage. Anat Rec 1969; 163: 497-508.
23. Cohen AB, Cline MJ: The human alveolar macrophage: Isolation, cultivation in vitro and studies of morphologic and functional characteristics. J Clin Invest 1971; 50: 1390-8.
24. Mann PEG, Cohen AB, Finley TN, Ladman AJ: Alveolar macrophages: structural and functional differences between nonsmokers and smokers of marijuana and tobacco. Lab Invest 1971; 25: 111-20.
25. Harris JO, Swenson EW, Johnson JE III: Human alveolar macrophages: comparison of phagocytic ability, glucose utilization, and ultastructure in smokers and nonsmokers. J Clin Invest 1970; 49: 2086-96.
26. Cantrell ET, Warr GA, Busbee DL, Martin RR: Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages by cigarette smoking. J Clin Invest 1973; 52: 1881-84.
27. Yeager Jr. H, Zimmet SM, Schwartz SL: Pinocytosis by human alveolar macrophages: comparison of smokers and nonsmokers. J Clin Invest 1974; 54: 247-51.
28. Kazmierowski JA, Gallin JI, Reynolds HY: Mechanisms for the inflammatory response in primate lungs: demonstration and partial characterization of an alveolar macrophage - derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest 1977; 59: 273-81.
29. Hunninghake GW, Gallin JI, Fauci AS: Immunologic reactivity in the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis 1978; 117: 15-23.
30. Gadek JE, Hunninghake GW, Zimmerman RL, Crystal RG: Regulation of the release of alveolar macrophage-derived neutrophil chemotactic factor. Am Rev Respir Dis 1980; 121: 723-33.
31. Merrill WW, Naegel GP, Matthay RA, Reynolds HY: Alveolar macrophage derived chemotactic factor. J Clin Invest 1980; 65: 268-76.
32. Hunninghake GW, Gadek JE, Fales HM, Crystal RG: Human alveolar macrophage - derived chemotactic factor for neutrophils. J Clin Invest 1980; 66: 473-83.
33. Nathan CF, Murray HW, Cohn ZA: The macrophage as an effector cell - current concepts. N Engl J Med 1980; 303: 622-6.
34. Strumpf IJ, Feld MK, Cornelius MJ, Keogh BA, Crystal RG: Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease. Chest 1981; 80: 268-71.
35. Davis GS, Brody AR, Landis JN, Graham WGB, Craighead JE, Green GM: Quantitation of inflammatory activity in interstitial pneumonitis by bronchofiberscopic pulmonary lavage. Chest 1976; 69 (suppl): 265-66.
36. Reynolds HY, Fulmer JD, Kazmierowski JA, Roberts WC, Frank MM. Crystal RG: Analysis of cellular and protein content of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. J Clin Invest 1977; 59: 165-75.
37. Weinberger SE, Kelman JA, Elson NA, et al: Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med 1978; 89: 459-66.
38. Daniele RP, Elias JA, Epstein PE, Rossman MD: Bronchoalveloar lavage: role in pathogenesis, diagnosis, and management of interstitial lung disease. Ann Intern Med 1985; 102: 93-108.
39. Davis GS, Brody AR, Craighead JE: Analysis of airspace and interstitial mononuclear cell populations in human diffuse interstitial lung disease. Am Rev Respir Dis 1978; 118: 7-15.
40. Hunninghake GW, Kawanami O, Ferrans VJ, Young RC Jr, Roberts WC, Crystal RG: Characterization of the Inflammatory and Immune Effector Cells in the Lung Parenchyma of Patients with Interstitial Lung Disease. Am Rev Respir Dis 1981; 123: 407-12.
41. Biserte G, Chretien J, Voisin C, Edited Proceedings: International symposium on bronchoalveolar lavage in man. Published by L'Institut National de la Sante et de la Recherche Medical 1976; 84: 1-527.
42. Haslam PL, Turton CWG, Lukoszek A, et al: Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35: 328-39.
43. Crystal RG, Reynolds HY, Kalica AR: Bronchoalveolar lavage. The report of an international conference. Chest 1986; 90: 122-31 (second BAL conference 5/16-18/1984, Columbia, Maryland).
44. Rudd RM, Haslam PL, Turner-Warwick M: Cryptogenic fibrosing alveolitis-relationship of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1-8.
45. Haslam PL: Bronchoalveolar lavage. Semin Respir Med 1984; 6: 55-70.
46. Leatherman JW, Michael AF, Schwartz BA, Hoidal JR: Lung T cells in hypersensitivity pneumonitis. Ann Intern Med 1984; 100: 390-2
47. Semenzato G, Chilosi M, Ossi E, et al: Bronchoalveolar lavage and lung histology - comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985; 132: 400-4.
48. Yeager HM, William MC, Beckman JF, Bayly TC, Beaman BL, Hawley RJ: Sarcoidosis: analysis of cells obtained by bronchial lavage. Am Rev Respir Dis 1977; 116: 951-5.
49. Hunninghake GW, Fulmer JD, Young RC Jr, Gadek JF, Crystal RG: Localization of the immune response in sarcoidosis. Am Rev Respir Dis 1979; 120: 49-57.
50. Dauber J, Rossman M, Daniele RP: Bronchoalveolar cell populations in acute sarcoidosis: observations in smoking and nonsmoking patients. J Lab Clin Med 1979; 94: 862-71.
51. Reynolds HY: Bronchoalveolar lavage - state of art. Am Rev Respir Dis 1987; 135: 250-63.
52. Gadek JE, Kelman JA, Fells G, et al: Collagenase in the lower Respiratory Tract of Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 1979; 301: 737-42.
53. Hunninghake GW, Gadek JE, Lawley TJ, Crystal RG: Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1981; 68: 259-69.
54. Martin TR, Altman LC, Albert RK, Henderson W: Leukotriene B4 production from human alveolar macrophages: A potential mechanism for amplifying inflammation in the lung. Am Rev Respir Dis 1984; 129: 106-11.
55. Carré PC, Mortenson RL, King TE Jr, Noble PW, Sable CL, Riches DWH: Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis: a potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991; 88: 1802-10.
56. Rennard SI, Hunninghake GW, Bitterman PB, Crystal RG: Production of fibronectin by the human alveolar macrophage: Mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci USA 1981; 78: 7147-51.
57. Rom WN, Basset P, Fells GA, Nukiwa T, Trapnell BC, Crystal RG: Alveolar macrophages release an insulin-like growth factor 1 - type molecule. J Clin Invest 1988; 82: 1685-93.
58. Mornex J-F, Martinet Y, Yamauchi K, et al: Spontaneous expression of the c-sis gene and release of a platelet derived growth factor-like molecule by human alveolar macrophages. J Clin Invest 1986; 78: 61-6.
59. Martinet Y, Rom WN, Grotendorst FR, Martin GR, Crystal RG: Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic fibrosis. N Engl J Med 1987; 317: 202-9.
60. Shaw RJ, Benedict SH, Clark RAF, King TE Jr: Pathogenesis of pulmonary fibrosis in interstitial lung disease: alveolar macrophage PDGF (B) gene activation and up-regulation by interferon gamma. Am Rev Respir Dis 1991; 143: 167-73.
61. McCormack FX, King TE Jr, Voelker DR, Robinson PC, Mason RJ: Idiopathic pulmonary fibrosis: abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991; 144: 160-6.
62. Ward PA, Hunninghake GW: Lung inflammation and fibrosis. Supplement: advances in pulmonary biology and medicine - celebrating fifty years at NHLBI. Am J Resp Crit Care Med 1998; 157: S123-9.
63. Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA: An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 1693-703.
64. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda, Y, Crystal RG: Intraluminal Fibrosis in Interstitial Lung Disorders. Am J Pathol 1986; 122: 433-61.
65. Crystal RG, Bitterman PB, Mossman B, et al, and Workshop panel: Future research directions in idiopathic pulmonary fibrosis. Summary of a National Heart, Lung, and Blood Institute Working Group. Am J Respir Crit Care Med 2002; 166: 236-46.
66. Cherniack RM, Crystal RG, Kalica AR: Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis 1991; 143: 680-3.
67. Katzenstein A-LA, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1310-5.
68. Katzenstein A-LA, Fiorelli RF: Non-specific interstitial pneumonia/fibrosis: histologic patterns and clinical significance. Am J Surg Pathol 1994; 18: 136-47.
69. Ziesche R, Hofbauer E, Wittman K, Petkov V, Block L-H: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-9.
70. Raghu G, Brown KK, Bradford WZ, et al, for the Idiopathic Pulmonary Fibrosis Study Group: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33.
71. Travis WD, Matsui K, Moss J, Ferrans VJ: Idiopathic non-specific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Am J Surg Pathol 2000; 24: 19-33.
72. Nakamura Y, Chida K, Suda T, et al: Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 235-41.
73. King TE Jr, Costabel U, Cordier J-F, et al, and Committee: Idiopathic pulmonary fibrosis: diagnosis and treatment (joint ATS and ERS statement). Am J Respir Crit Care Med 2000; 161: 646-64.
74. Selman M, King TE Jr, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
75. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-25.
76. Antoniou KM, Alexandrakis MG, Sfiridaki K, et al: Th1 cytokine pattern (1L-12 and 1L-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 105-10.
77. Hashimoto N, Jin IT, Liu T, Chensue W, Phan SIT: Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113: 234-52.
78. Phillips RJ, Burdick MD, Hong K, et al: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-46.
79. Beeh KM, Beier J, Kornmann O, Buhl R: Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 138-43.
80. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, Crystal RG. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med 1986; 314: 1343-7.